Acerus Pharmaceuticals Corp (ASP):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Acerus Pharmaceuticals Corp (ASP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9950
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:58
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Acerus Pharmaceuticals Corp (Acerus), formerly Trimel Pharmaceuticals Corporation develops, manufactures, markets and distributes novel innovative branded products. It focuses on providing men’s and women’s health. The company uses its proprietary drug delivery technology platforms, which include a bioadhesive nasal gel and the TriVair Deposition/Dispersion System, for the delivery of its products. Its product portfolio includes Estrace, which is approved in Canada for relief from menopausal symptoms; and Natesto, a testosterone nasal gel, which is approved by the US FDA for the treatment of male hypogonadism and filed for approval in Canada. Acerus is also developing Tefina (testosterone nasal gel) for women with female sexual dysfunction. Acerus is headquartered in Mississauga, Ontario, Canada.

Acerus Pharmaceuticals Corp (ASP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Acerus Pharmaceuticals Corp, Medical Devices Deals, 2012 to YTD 2018 10
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Trimel Pharma Acquires Canadian Rights to Estrace from Shire for USD41.3 Million 13
Partnerships 15
Trimel Pharma Enters Into Co-Development Agreement With European Company 15
Licensing Agreements 16
Acerus Pharma Enters into Licensing Agreement with Pharmanest 16
Producto Cientificos Enters into Licensing Agreement with Acerus Pharma 17
Acerus Pharma Enters into Distributor and Licensing Agreement with Metuchen Pharma 18
Acerus Pharma Enters into Licensing Agreement with Viramal 19
Apsen Farmaceutica Enters into Licensing Agreement with Acerus Pharma 20
Eu Hwa Enters into Licensing Agreement with Acerus Pharma for NATESTO 21
medac Enters into Licensing Agreement with Acerus Pharma for NATESTO 22
Therios Healthcare Enters into Licensing Agreement with Acerus Pharma for NATESTO 23
Aytu BioScience Enters into Licensing Agreement with Acerus Pharma 24
Acerus Pharma Enters into Licensing Agreement with Medinova 25
Acerus Pharma Enters into Licensing and Distribution Agreement with Innovus Pharma 26
Equity Offering 27
Acerus Pharma Raises USD5.1 Million in Private Placement of Units 27
Acerus Pharma Raises USD2 Million in Private Placement of Shares 29
Trimel Pharma Raises USD16.6 Million in Private Placement of Shares 30
Acerus Pharma Raises USD2.1 Million in Private Placement of Shares 31
Trimel Pharma Announces Full Exercise Of Underwriter’s Option For Public Offering Of Shares For US$45 Million 32
Trimel Pharma Announces Rights Offering Of Shares 34
Trimel Pharma Completes Public Offering Of Units For US$13 Million 35
Debt Offering 37
Trimel Pharma Raises USD25 Million in Private Placement of 9.5% Convetible Note Due 2015 37
Acerus Pharmaceuticals Corp – Key Competitors 38
Acerus Pharmaceuticals Corp – Key Employees 39
Acerus Pharmaceuticals Corp – Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Recent Developments 41
Financial Announcements 41
Aug 13, 2018: Acerus Reports second quarter 2018 financial results 41
May 15, 2018: Acerus Reports First Quarter 2018 Financial Results 44
Nov 07, 2017: Acerus Reports Third Quarter 2017 Financial Results 46
Aug 11, 2017: Acerus Reports Second Quarter 2017 Financial Results 48
Mar 08, 2017: Acerus Reports Fourth Quarter and Full Year 2016 Financial Results 50
Corporate Communications 52
Jun 05, 2018: Acerus Announces Resignation Of Luc Mainville As Director 52
Mar 29, 2018: Acerus Announces Executive Leadership Change 53
Dec 07, 2017: Acerus Appoints Mr. Mark Lievonen to its Board of Directors 54
Oct 02, 2017: Acerus Announces Executive Leadership Change 55
May 05, 2017: Acerus Announces Appointment of Ken Yoon as Chief Financial Officer 56
Legal and Regulatory 57
Apr 10, 2018: Acerus Announces Settlement of Melnyk Litigation 57
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58

List of Tables
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Acerus Pharmaceuticals Corp, Deals By Therapy Area, 2012 to YTD 2018 9
Acerus Pharmaceuticals Corp, Medical Devices Deals, 2012 to YTD 2018 10
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Trimel Pharma Acquires Canadian Rights to Estrace from Shire for USD41.3 Million 13
Trimel Pharma Enters Into Co-Development Agreement With European Company 15
Acerus Pharma Enters into Licensing Agreement with Pharmanest 16
Producto Cientificos Enters into Licensing Agreement with Acerus Pharma 17
Acerus Pharma Enters into Distributor and Licensing Agreement with Metuchen Pharma 18
Acerus Pharma Enters into Licensing Agreement with Viramal 19
Apsen Farmaceutica Enters into Licensing Agreement with Acerus Pharma 20
Eu Hwa Enters into Licensing Agreement with Acerus Pharma for NATESTO 21
medac Enters into Licensing Agreement with Acerus Pharma for NATESTO 22
Therios Healthcare Enters into Licensing Agreement with Acerus Pharma for NATESTO 23
Aytu BioScience Enters into Licensing Agreement with Acerus Pharma 24
Acerus Pharma Enters into Licensing Agreement with Medinova 25
Acerus Pharma Enters into Licensing and Distribution Agreement with Innovus Pharma 26
Acerus Pharma Raises USD5.1 Million in Private Placement of Units 27
Acerus Pharma Raises USD2 Million in Private Placement of Shares 29
Trimel Pharma Raises USD16.6 Million in Private Placement of Shares 30
Acerus Pharma Raises USD2.1 Million in Private Placement of Shares 31
Trimel Pharma Announces Full Exercise Of Underwriter's Option For Public Offering Of Shares For US$45 Million 32
Trimel Pharma Announces Rights Offering Of Shares 34
Trimel Pharma Completes Public Offering Of Units For US$13 Million 35
Trimel Pharma Raises USD25 Million in Private Placement of 9.5% Convetible Note Due 2015 37
Acerus Pharmaceuticals Corp, Key Competitors 38
Acerus Pharmaceuticals Corp, Key Employees 39
Acerus Pharmaceuticals Corp, Subsidiaries 40

List of Figures
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Acerus Pharmaceuticals Corp, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Acerus Pharmaceuticals Corp (ASP):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • CEWE Stiftung & Co.KGaA (CWC):企業の財務・戦略的SWOT分析
    CEWE Stiftung & Co.KGaA (CWC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • NovaDigm Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary NovaDigm Therapeutics Inc (NovaDigm) is a developer of immunotherapeutics and preventative vaccines to protect patients from fungal and bacterial diseases. The company’s products include NDV-3 vaccines, ALS3 vaccines, vaccine clinical supplies, bacterial and fungal vaccine antigens, vaginal …
  • Immunomic Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Immunomic Therapeutics Inc (ITI) is a biotechnology company that specializes in developing vaccines based on the patented lysosomal associated membrane protein or lamp technology. The company's pipeline product portfolio drugs for allergy vaccine therapy and oncology immunotherapy. It develo …
  • Harley-Davidson, Inc.:企業の戦略・SWOT・財務情報
    Harley-Davidson, Inc. - Strategy, SWOT and Corporate Finance Report Summary Harley-Davidson, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Challenger Ltd.:企業の戦略・SWOT・財務情報
    Challenger Ltd. - Strategy, SWOT and Corporate Finance Report Summary Challenger Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • NTPC Ltd (NTPC):電力:M&Aディール及び事業提携情報
    Summary NTPC Ltd (NTPC) is a Public sector undertaking energy conglomerate. It has presence in the entire value chain of the power generation business. The company produces electricity and sells that to state power utilities on wholesale basis. NTPC generates power using coal, gas, liquid fuel and h …
  • Papyrus Australia Limited (PPY):企業の財務・戦略的SWOT分析
    Papyrus Australia Limited (PPY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Streamwide SA (ALSTW):企業の財務・戦略的SWOT分析
    Streamwide SA (ALSTW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Avivagen Inc (VIV):企業の財務・戦略的SWOT分析
    Summary Avivagen Inc (Avivagen), formerly Chemaphor Inc is a biotechnology company that provides drug development and animal healthcare products. The company develops science-based, natural health products for animals. It operates through divisions including companion animal health, food animal heal …
  • Beacon Biomedical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Beacon Biomedical Inc (Beacon) is a medical diagnostic device company that offers point-of-care blood test systems. The company offers its product portfolio in the therapeutic areas of breast cancer, colorectal cancer and lung cancer. It holds two patented technologies such as signaling prot …
  • Ethicon US LLC:医療機器:M&Aディール及び事業提携情報
    Summary Ethicon US LLC (Ethicon), a subsidiary of Johnson and Johnson, is a medical equipment company which operates through Ethicon Inc, and Ethicon Endo-Surgery Inc. It develops and markets surgical instruments and devices. Its major products include staplers, energy devices, clip appliers, trocar …
  • Mitsui Oil Exploration Co Ltd:企業の戦略的SWOT分析
    Mitsui Oil Exploration Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Companhia Energetica de Minas Gerais – CEMIG:企業のM&A・事業提携・投資動向
    Companhia Energetica de Minas Gerais - CEMIG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Companhia Energetica de Minas Gerais - CEMIG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, d …
  • Jiangsu Nhwa Pharmaceutical Corp Ltd (002262)-製薬・医療分野:企業M&A・提携分析
    Summary Jiangsu Nhwa Pharmaceutical Corp Ltd (Jiangsu) is a pharmaceutical company that research, develops and manufactures central nervous system medicines. The company offers psychiatrical, anesthetic and neurological medicines including anti-anxiety agent, anti-psychopathic drug, antiepileptic dr …
  • EyeGate Pharmaceuticals Inc (EYEG)-医療機器分野:企業M&A・提携分析
    Summary EyeGate Pharmaceuticals Inc (EyeGate) is a clinical-stage specialty pharmaceutical company that offers eye care medicines. The company offers macular edema and non-infectious anterior uveitis. It offers technologies for most prevalent issues in ophthalmic care; the existing lack of patient a …
  • Transocean Ltd.:戦略・SWOT・企業財務分析
    Transocean Ltd. - Strategy, SWOT and Corporate Finance Report Summary Transocean Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Fifth Street Finance Corp.:企業のM&A・事業提携・投資動向
    Fifth Street Finance Corp. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Fifth Street Finance Corp. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Delphi Automotive Plc (APTV):企業の財務・戦略的SWOT分析
    Delphi Automotive Plc (APTV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Living Cell Technologies Ltd (LCT):製薬・医療:M&Aディール及び事業提携情報
    Summary Living Cell Technologies Ltd (LCT) is a biotechnology company that develops cell-based therapeutics for the treatment of neurological diseases, diabetes, and stroke and hearing loss. It focuses on discovering regenerative treatments which restore function using naturally occurring cells. LCT …
  • Haldia Petrochemicals Ltd:企業の戦略的SWOT分析
    Haldia Petrochemicals Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆